What it is
KLOW is a combination product, not a single peptide. It packs four research peptides into one vial, typically at a fixed ratio of GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg (80mg total). It builds on the three-peptide GLOW blend by adding KPV. It is sold strictly as a research chemical, labelled "not for human consumption."
The four components
Each part has its own page or section in this library. In brief:
- GHK-Cu — copper tripeptide, best evidenced for topical skin and collagen. See full page
- BPC-157 — tissue-repair peptide, animal-heavy evidence, not approved. See full page
- TB-500 — thymosin beta-4 fragment for cell migration/repair, mostly animal data. See full page
- KPV — a small anti-inflammatory tripeptide derived from alpha-MSH, studied for calming inflammatory signalling (for example TNF-α and IL-6) and supporting gut and skin barriers.
The theory behind the blend
The rationale is that the four peptides target complementary pathways at once: collagen synthesis (GHK-Cu), inflammation via NF-κB (KPV), growth-factor modulation (BPC-157) and cell migration (TB-500). The marketing logic is "multi-pathway recovery." Whether these mechanisms actually combine to produce a meaningful, safe effect in humans has not been tested.
Why blends add risk
Beyond the lack of testing, combining compounds compounds the unknowns. Interaction effects are not studied. If something goes wrong, it is impossible to know which component caused it. And because these are research chemicals with no regulatory oversight, purity and dosing accuracy rest entirely on the seller. BPC-157 and TB-500 are also prohibited in tested sport.
Where it stands
KLOW is a marketing construct assembled from four unapproved peptides. It carries all the limitations of its parts, plus the added uncertainty of an untested combination. It is research-only material with no human efficacy or safety data on the blend.